EATG » Switch from TDF to TAF improves kidney and bone markers

Switch from TDF to TAF improves kidney and bone markers

The Body reports: Proteinuria, albuminuria and bone mineral density (BMD) improved significantly in HIV-positive people with mild or moderate renal impairment who switched to once-daily coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF, Genvoya) for 48 weeks. Creatinine clearance did not change significantly after the switch in this single-arm open-label study.

Source: http://www.thebodypro.com/content/78259/kidney-and-bone-markers-improve-in-patients-with-r.html

 

News categories: HIV treatment, Quality of life, R&D